Phase Ia/Ib Study of the Selective MET Inhibitor, Savolitinib, in Patients with Advanced Solid Tumors: 
Safety, Efficacy, and Biomarkers

BACKGROUND: Savolitinib has shown good tolerability and preliminary efficacy, but efficacy biomarkers require investigation. The main purpose of this study was to confirm in Chinese patients the recommended phase II dose (RP2D) of savolitinib and to explore overall benefit in tumors bearing c-Met ab...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Yakun, Liu, Tianshu, Chen, Gongyan, Gong, Jifang, Bai, Yuxian, Zhang, Tao, Xu, Nong, Liu, Li, Xu, Jianming, He, Jianxing, Liu, Yunpeng, Zhang, Li, Jiang, Da, Wang, Mengzhao, Chang, Jianhua, Li, Wei, Bai, Chunmei, Zhou, Jinghong, Wang, Jian, Ren, Yongxin, Zhang, Liya, Su, Weiguo, Liu,, Baorui, Shen, Lin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Clinical Trial Results
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9074963/
https://www.ncbi.nlm.nih.gov/pubmed/35445725
http://dx.doi.org/10.1093/oncolo/oyab066

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9074963/
https://www.ncbi.nlm.nih.gov/pubmed/35445725
http://dx.doi.org/10.1093/oncolo/oyab066

Ejemplares similares